Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion
The company allocated €56 million to research and development for next-generation line solutions
The company allocated €56 million to research and development for next-generation line solutions
Integrated eCOA technology and rater training aim to reduce variability and strengthen ClinRO outcomes
Revvity is positioning its technologies as a connected engine for discovery
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Muted movement reflects consolidation phase as investors await earnings triggers
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The company reported net revenue of SEK 13.5 million for the full year 2025
Subscribe To Our Newsletter & Stay Updated